Reata Pharmaceuticals's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Reata Pharmaceuticals is set to release its Q1 earnings on May 6, with analysts predicting a quarterly loss of $2.1 per share on sales of $1.19 million. This represents a significant decline from the previous year's EPS and revenue. The company's stock has decreased by 41.89% over the past year, and investors should watch for potential stock movement following the earnings release and conference call.
May 05, 2021 | 2:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Reata Pharmaceuticals is expected to report a significant decline in earnings and revenue for Q1, with a predicted loss of $2.1 per share. The stock has already seen a 41.89% decline over the past year, and further movement is anticipated following the earnings release and conference call.
The expected decline in earnings and revenue, along with the significant drop in stock price over the past year, suggests a negative short-term impact on Reata Pharmaceuticals' stock. The earnings release and conference call could lead to further stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100